Rigel Pharma (RIGL) Tops Q4 EPS by 10c

Rigel Pharma (NASDAQ: RIGL) reported Q4 EPS of $0.01, $0.10 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $51.3 million versus the consensus estimate of $36.52 million.

As of December 31, 2022, Rigel had cash, cash equivalents and short-term investments of $58.2 million, compared to $125.0 million as of December 31, 2021.

For earnings history and earnings-related data on Rigel Pharma (RIGL) click here.

You May Also Be Interested In

• JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Benchmark Reiterates Buy Rating on Cineverse (CNVS) Ahead of Q4 Results